Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

4811 - Comprehensive genomic profiling of thymic carcinoma in a sample Chinese population


28 Sep 2019


Poster Display session 1


Tumour Site

Thymoma and Thymic Cancer


Baohui Han


Annals of Oncology (2019) 30 (suppl_5): v747-v755. 10.1093/annonc/mdz266


B. Han1, W. Fang2, W. Zhang1, S. Wang1, L.Z. Zhang1, B. Zhang1, M. Hu1, Y. Zhao1, J. Qian1

Author affiliations

  • 1 Pulmonary Medicine, Shanghai Chest Hospital, 200030 - Shanghai/CN
  • 2 Thoracic Surgery, Shanghai Chest Hospital, 200030 - Shanghai/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4811


Thymic carcinomas (TC) is a kind of a malignant intrathoracic tumor. Herein, we examined the clinicopathological characteristics and analyzed comprehensive genomic profiling (CGP) in 47 TC patients to elucidate the potentially clinically relevant genomic alterations (CRGAs) in this population.


47 stage I-IV TC patients who underwent surgery at Shanghai Chest Hospital between 2015 and 2017 were analyzed. These patients were sequenced by FoundationOne CDx (F1CDx) which is a FDA approved platform conducted by DIAN (Hangzhou Lab) with the licensed technologies. In this study, we focus on CRGAs which are known or likely pathogenic alterations.


The 47 TC patients included 27 thymic squamous cell carcinoma (TSCC), 14 neuroendocrine tumors of the thymus (NETT) and 7 mixed subtype of TSCC and NETT. The median age of TSCC, NETT and mixed subtype was 59.5, 65 and 74, respectively. The median number of CRGAs in TSCC, NETT and mixed subtype were 1 (range 0-10), 2 (range 0-3) and 2 (range 0-4), respectively. Only one TSCC patient was microsatellite instability-high (MSI-H), which also has the highest TMB (21 Muts/Mb). Among all the four patients with TMB larger than 10 Muts/Mbs, three were TSCC and one was mixed subtype. The top ranked altered genes in TSCC were TP53 (30%), CDKN2A (26), CDKN2B (19%) and ASXL1 (15%). In NETT, the top mutated genes were MEN1 (36%), STAG2 (14%), CDKN2A (14%) and HRAS (14%). Furthermore, the top ranked mutated genes in mixed subtype were TP53 (29%) and CDKN2A (29%). Notably, TP53, ASXL1, TET2, MLL2, EP30, BAP1 were only mutated in TSCC or mixed subtypes. However, mutated of MEN1, STAG2 and HRAS were also founded in NETT subtype.


This was the largest cohort of CGP for TC till now in a sample Chinese population. TSCC and NETT have very different mutated landscapes, while the mixed subtype was more similar with TSCC. The number of CRGA range from 0 to 10 also demonstrated a high tumor heterogeneity for TSCC. In addition, the top mutated genes in TSCC and NETT founded in this study were different from the published results which focused on metastatic thymic carcinoma (mTC). Given the limited treatment options and poor prognosis of patients with TC, CGP has the potential to identify new treatment paradigms and meet an unmet clinical need for this disease.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Shanghai science and technology commission.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.